Abstract
Alzheimers Disease (AD) is a progressive and devastating neurodegenerative disorder affecting the brain. It is the most common form of late-life dementia and is one of the leading causes of death in the developed world. Due to the ageing population and improvement in diagnosis it is expected that the number of diagnosed AD patients will increase from the current level of ∼5 million to ∼22 million by 2025. Acetylcholine-based therapies, currently the only treatment regimes approved for AD, will also be the basis for treatment in the near future. However, progression of the disease is not affected by acetylcholinesterase inhibitors; rather it is a symptomatic treatment which can delay deterioration of cognitive symptoms for up to six months. Pharmaceutical companies are now investing their efforts in the development of diseasemodifying treatments for AD. The rationale for new drug design is based on the amyloid cascade hypothesis, which proposes that accumulation of amyloid beta peptide is the key event that triggers the pathological events in AD. The most promising, emerging approaches for the treatment of AD, targeting the release, the aggregation and the clearance of Abeta will be discussed.
Keywords: alzheimer disease, amyloid cascade hypothesis, amyloid beta peptide, amyloid precursor protein, disease modifying therapeutic
Current Neuropharmacology
Title: Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Volume: 2 Issue: 3
Author(s): Christian Czech and Celine Adessi
Affiliation:
Keywords: alzheimer disease, amyloid cascade hypothesis, amyloid beta peptide, amyloid precursor protein, disease modifying therapeutic
Abstract: Alzheimers Disease (AD) is a progressive and devastating neurodegenerative disorder affecting the brain. It is the most common form of late-life dementia and is one of the leading causes of death in the developed world. Due to the ageing population and improvement in diagnosis it is expected that the number of diagnosed AD patients will increase from the current level of ∼5 million to ∼22 million by 2025. Acetylcholine-based therapies, currently the only treatment regimes approved for AD, will also be the basis for treatment in the near future. However, progression of the disease is not affected by acetylcholinesterase inhibitors; rather it is a symptomatic treatment which can delay deterioration of cognitive symptoms for up to six months. Pharmaceutical companies are now investing their efforts in the development of diseasemodifying treatments for AD. The rationale for new drug design is based on the amyloid cascade hypothesis, which proposes that accumulation of amyloid beta peptide is the key event that triggers the pathological events in AD. The most promising, emerging approaches for the treatment of AD, targeting the release, the aggregation and the clearance of Abeta will be discussed.
Export Options
About this article
Cite this article as:
Czech Christian and Adessi Celine, Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359666
DOI https://dx.doi.org/10.2174/1570159043359666 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Applications of Integrated Data Mining Methods to Exploring Natural Product Space for Acetylcholinesterase Inhibitors
Combinatorial Chemistry & High Throughput Screening Body-centred and Object-centred Motor Imagery in Alzheimer's Disease
Current Alzheimer Research The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?
Recent Patents on CNS Drug Discovery (Discontinued) AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Editorial [Hot topic: Polyunsaturated Fatty Acids and Human Health: A Critical Appraisal of the Evidence (Executive Editor: Antonio Cherubini)]
Current Pharmaceutical Design Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Synthesis and Biological Activities of Naturally Functionalized Polyamines: An Overview
Current Medicinal Chemistry Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment
Current Medicinal Chemistry A Dual Activity of ROS and Oxidative Stress on Adult Neurogenesis and Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Current Alzheimer Research Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design